Acadian Asset Management LLC recently announced the acquisition of new stake in Avalo Therapeutics Inc (NASDAQ:AVTX). This fresh investment now brings its stake to 0.15% valued currently at $19831.0. In addition, Baader Bank AG raised its holdings by 0.18 million to 0.18 million shares. And Virtu Americas LLC has lifted its position by 468.67% or 0.15 million shares – to 0.19 million shares.
With over 21.34 million Avalo Therapeutics Inc (AVTX) shares trading Friday and a closing price of $0.06 on the day, the dollar volume was approximately $1.28 million. The shares have shown a negative half year performance of -88.80% and its price on 12/22/23 gained nearly 12.00%. Currently, there are 192.38M common shares owned by the public and among those 192.15M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 37 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 34 of these insider trades were purchases, accounting for 658,840 shares. Insider sales of the common stock occurred on 3 occasions, with total insider shares sold totaling 4,354,138 shares.
The top 3 mutual fund holders in Avalo Therapeutics Inc are iShares Core S&P Total US Stock M, Fidelity Extended Market Index Fu, and Vanguard Extended Market Index Fu. iShares Core S&P Total US Stock M owns 3.25 million shares of the company’s stock, all valued at over $0.23 million. Vanguard Extended Market Index Fu now owns shares totaling to 0.04% of the shares outstanding.
However, the script later moved the day high at 0.0590, up 12.00%. The company’s stock has a 5-day price change of -6.67% and -65.64% over the past three months. AVTX shares are trading -98.89% year to date (YTD), with the 12-month market performance down to -98.88% lower. It has a 12-month low price of $0.03 and touched a high of $5.40 over the same period. AVTX has an average intraday trading volume of 62.56 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -9.00%, -38.16%, and -95.06% respectively.
Institutional ownership of Avalo Therapeutics Inc (NASDAQ: AVTX) shares accounts for 0.70% of the company’s 192.38M shares outstanding. Mutual fund holders own 1.24%, while other institutional holders and individual stakeholders account for 1.84% and -1.14% respectively.
It has a market capitalization of $10.77M and a beta (3y monthly) value of 1.04. The earnings-per-share (ttm) stands at -$2.59. Price movements for the stock have been influenced by the stock’s volatility, which stands at 20.02% over the week and 23.91% over the month.
Analysts forecast that Avalo Therapeutics Inc (AVTX) will achieve an EPS of -$0.02 for the current quarter, -$0.02 for the next quarter and -$0.07 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.02 while analysts give the company a high EPS estimate of -$0.02. Comparatively, EPS for the current quarter was -$1.04 a year ago. Earnings per share for the fiscal year are expected to increase by 90.97%, and 82.50% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Avalo Therapeutics Inc (AVTX) as a “Hold” at a consensus score of 3.00. Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 1 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the AVTX, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Outperform rating for the stock in a research note on September 24, 2021, with the firm’s price target at $6.
